What’s New? - Preliminary Data Demonstrates KIO-301 Restored Visual Function in Retinitis Pigmentosa Study.


We’re excited about the products we have in the pipeline and the impact they will have on patients.

Product Indication Preclin Phase One Phase Two Phase Three
KIO-301 (Intravitreal) Retinitis Pigmentosa
KIO-101 (Eyedrop) Ocular Manifestations of Rheumatoid Arthritis
KIO-201 (Eyedrop) Persistent Corneal Epithelial Defects
KIO-201 (Eyedrop) Corneal Surgical Wounds
KIO-301 received Orphan Drug Designation from the FDA on March 17, 2022.
These therapeutics are still in development and are not yet approved for commercial use.
Loading RSS Feed